Clinical Trial Update: meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating the mechanisms and safety of SGLT2 inhibition in people on peritoneal dialysis; currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Kidney Disease

Drugs mentioned

• SGLT2 inhibitors (SGLT2 inhibitor)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Peritoneal Dialysis Complication, End Stage Kidney Disease | Phase 3 | Status: RECRUITING